| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.785 | 0.003 | 0.785 | Diuretic | 0.762 0.003 DBMET01014 | ||
| 0.766 | 0.004 | 0.808 | Vasodilator, peripheral | 0.808 0.004 DBMET01014 0.326 0.085 DBMET00840 | DBMET01014 | |
| 0.649 | 0.009 | 0.649 | Spasmolytic | 0.496 0.024 DBMET01014 | ||
| 0.544 | 0.002 | 0.622 | Angiotensin-converting enzyme inhibitor | 0.622 0.002 DBMET01014 | DBMET01014 | |
| 0.539 | 0.011 | 0.539 | Vasodilator, coronary | 0.451 0.023 DBMET01014 | ||
| 0.521 | 0.01 | 0.521 | Vasodilator | 0.509 0.011 DBMET01014 | ||
| 0.507 | 0.028 | 0.507 | Immunostimulant | 0.492 0.03 DBMET01014 0.158 0.148 DBMET00840 | ||
| 0.476 | 0.013 | 0.492 | Psychostimulant | 0.492 0.011 DBMET01014 0.214 0.073 DBMET00840 | DBMET01014 | |
| 0.428 | 0.024 | 0.428 | Cardiotonic | 0.421 0.025 DBMET01014 | ||
| 0.441 | 0.07 | 0.476 | Cyclophilin D inhibitor | 0.476 0.058 DBMET01014 | DBMET01014 | |
| 0.39 | 0.052 | 0.39 | Antithrombotic | 0.363 0.06 DBMET01014 0.229 0.144 DBMET00840 | ||
| 0.336 | 0.006 | 0.366 | Neurotrophic factor | 0.366 0.005 DBMET01014 | DBMET01014 | |
| 0.378 | 0.051 | 0.414 | Immunomodulator | 0.412 0.04 DBMET01014 0.414 0.04 DBMET00840 | DBMET00840 | |
| 0.352 | 0.038 | 0.39 | Platelet antagonist | 0.39 0.029 DBMET01014 | DBMET01014 | |
| 0.385 | 0.083 | 0.385 | Histamine release inhibitor | 0.273 0.139 DBMET01014 | ||
| 0.342 | 0.049 | 0.45 | Interleukin 2 agonist | 0.406 0.026 DBMET01014 0.45 0.015 DBMET00840 | DBMET00840 | |
| 0.324 | 0.038 | 0.358 | Interleukin agonist | 0.358 0.027 DBMET01014 0.262 0.07 DBMET00840 | DBMET01014 | |
| 0.327 | 0.044 | 0.327 | Hypoglycemic | 0.296 0.054 DBMET01014 | ||
| 0.304 | 0.023 | 0.357 | Thrombolytic | 0.357 0.016 DBMET01014 | DBMET01014 | |
| 0.334 | 0.06 | 0.334 | 5 Hydroxytryptamine release stimulant | 0.226 0.102 DBMET01014 | ||
| 0.295 | 0.029 | 0.335 | Anticoagulant | 0.335 0.023 DBMET01014 | DBMET01014 | |
| 0.304 | 0.048 | 0.326 | Angiogenesis stimulant | 0.326 0.04 DBMET01014 0.147 0.124 DBMET00840 | DBMET01014 | |
| 0.353 | 0.113 | 0.353 | 5 Hydroxytryptamine release inhibitor | |||
| 0.241 | 0.004 | 0.241 | Acetylcholine release stimulant | 0.159 0.012 DBMET01014 0.144 0.02 DBMET00840 | ||
| 0.315 | 0.082 | 0.315 | Cholesterol antagonist | 0.236 0.136 DBMET01014 | ||
| 0.233 | 0.004 | 0.233 | Leukocyte elastase inhibitor | 0.155 0.005 DBMET01014 | ||
| 0.227 | 0.002 | 0.246 | Prolyl endopeptidase inhibitor | 0.246 0.002 DBMET01014 | DBMET01014 | |
| 0.274 | 0.054 | 0.321 | Gastrin inhibitor | 0.321 0.021 DBMET01014 | DBMET01014 | |
| 0.339 | 0.126 | 0.364 | Calcium channel L-type activator | 0.262 0.193 DBMET01014 0.364 0.107 DBMET00840 | DBMET00840 | |
| 0.239 | 0.029 | 0.239 | Thiol protease inhibitor | 0.214 0.035 DBMET01014 | ||
| 0.224 | 0.016 | 0.268 | Aminopeptidase B inhibitor | 0.268 0.011 DBMET01014 | DBMET01014 | |
| 0.299 | 0.095 | 0.299 | Transcription factor NF kappa B inhibitor | 0.268 0.115 DBMET01014 | ||
| 0.307 | 0.111 | 0.323 | Immunosuppressant | 0.306 0.111 DBMET01014 0.323 0.101 DBMET00840 | DBMET00840 | |
| 0.263 | 0.085 | 0.47 | Insulysin inhibitor | 0.268 0.081 DBMET01014 0.47 0.013 DBMET00840 | DBMET00840 | |
| 0.307 | 0.137 | 0.346 | Analgesic | 0.346 0.11 DBMET01014 | DBMET01014 | |
| 0.185 | 0.029 | 0.228 | Cell adhesion inhibitor | 0.228 0.018 DBMET01014 0.109 0.075 DBMET00840 | DBMET01014 | |
| 0.19 | 0.041 | 0.223 | Neurotensin receptor agonist | 0.223 0.026 DBMET01014 0.171 0.061 DBMET00840 | DBMET01014 | |
| 0.173 | 0.035 | 0.173 | Proteasome inhibitor | 0.154 0.044 DBMET01014 | ||
| 0.2 | 0.064 | 0.2 | P-glycoprotein inhibitor | 0.177 0.082 DBMET01014 | ||
| 0.174 | 0.04 | 0.174 | Anesthetic local | |||
| 0.123 | 0.006 | 0.189 | Dipeptidyl peptidase inhibitor | 0.189 0.004 DBMET01014 0.05 0.041 DBMET00840 | DBMET01014 | |
| 0.178 | 0.068 | 0.257 | Growth hormone agonist | 0.257 0.042 DBMET01014 0.149 0.088 DBMET00840 | DBMET01014 | |
| 0.216 | 0.11 | 0.235 | Tyrosine 3 hydroxylase inhibitor | 0.235 0.084 DBMET01014 | DBMET01014 | |
| 0.127 | 0.021 | 0.161 | Cell adhesion molecule inhibitor | 0.161 0.013 DBMET01014 | DBMET01014 | |
| 0.118 | 0.013 | 0.118 | Elastase 1 inhibitor | 0.103 0.019 DBMET01014 | ||
| 0.238 | 0.141 | 0.295 | Sodium/bile acid cotransporter inhibitor | 0.295 0.084 DBMET01014 | DBMET01014 | |
| 0.098 | 0.005 | 0.109 | Prolactin release inhibitor | 0.109 0.004 DBMET01014 0.065 0.035 DBMET00840 | DBMET01014 | |
| 0.142 | 0.053 | 0.203 | Cathepsin H inhibitor | 0.203 0.022 DBMET01014 | DBMET01014 | |
| 0.124 | 0.036 | 0.167 | Folate antagonist | 0.167 0.017 DBMET01014 | DBMET01014 | |
| 0.129 | 0.041 | 0.129 | Protease inhibitor | 0.127 0.042 DBMET01014 | ||
| 0.091 | 0.003 | 0.165 | Angiotensin-converting enzyme 2 inhibitor | 0.165 0.003 DBMET01014 | DBMET01014 | |
| 0.113 | 0.025 | 0.131 | Analgesic, opioid | 0.131 0.019 DBMET01014 | DBMET01014 | |
| 0.213 | 0.128 | 0.32 | 5 Hydroxytryptamine uptake stimulant | 0.32 0.036 DBMET01014 | DBMET01014 | |
| 0.098 | 0.014 | 0.205 | NMDA 2A receptor antagonist | 0.205 0.005 DBMET01014 | DBMET01014 | |
| 0.119 | 0.037 | 0.155 | Opioid antagonist | 0.155 0.024 DBMET01014 0.093 0.054 DBMET00840 | DBMET01014 | |
| 0.104 | 0.023 | 0.104 | Calcium channel L-type blocker | |||
| 0.118 | 0.037 | 0.127 | Interleukin 1 beta converting enzyme inhibitor | 0.127 0.03 DBMET01014 | DBMET01014 | |
| 0.083 | 0.005 | 0.127 | Neutral endopeptidase inhibitor | 0.127 0.004 DBMET01014 | DBMET01014 | |
| 0.085 | 0.009 | 0.103 | HCV NS3/NS4A protease inhibitor | 0.103 0.004 DBMET01014 0.051 0.031 DBMET00840 | DBMET01014 | |
| 0.087 | 0.014 | 0.087 | Elastase inhibitor | 0.084 0.014 DBMET01014 | ||
| 0.109 | 0.042 | 0.181 | NMDA receptor antagonist | 0.181 0.017 DBMET01014 | DBMET01014 | |
| 0.095 | 0.029 | 0.101 | Thrombin inhibitor | 0.101 0.025 DBMET01014 | DBMET01014 | |
| 0.101 | 0.035 | 0.149 | Hematopoietic | 0.116 0.024 DBMET01014 0.149 0.015 DBMET00840 | DBMET00840 | |
| 0.074 | 0.009 | 0.126 | Dipeptidyl peptidase IV inhibitor | 0.126 0.004 DBMET01014 0.041 0.039 DBMET00840 | DBMET01014 | |
| 0.135 | 0.072 | 0.144 | Bone formation stimulant | 0.144 0.064 DBMET01014 | DBMET01014 | |
| 0.095 | 0.033 | 0.128 | Opioid mu receptor antagonist | 0.128 0.023 DBMET01014 0.069 0.047 DBMET00840 | DBMET01014 | |
| 0.169 | 0.108 | 0.174 | Insulin sensitizer | 0.174 0.103 DBMET01014 | DBMET01014 | |
| 0.105 | 0.052 | 0.115 | Falcipain inhibitor | 0.115 0.046 DBMET01014 | DBMET01014 | |
| 0.093 | 0.043 | 0.109 | Opioid kappa receptor antagonist | 0.109 0.028 DBMET01014 | DBMET01014 | |
| 0.101 | 0.051 | 0.111 | Falcipain 2 inhibitor | 0.111 0.046 DBMET01014 | DBMET01014 | |
| 0.083 | 0.035 | 0.125 | Opioid delta receptor antagonist | 0.125 0.025 DBMET01014 0.074 0.038 DBMET00840 | DBMET01014 | |
| 0.136 | 0.089 | 0.153 | Insulin secretagoues | 0.153 0.072 DBMET01014 | DBMET01014 | |
| 0.09 | 0.043 | 0.09 | Chymotrypsin inhibitor | 0.086 0.048 DBMET01014 0.082 0.051 DBMET00840 | ||
| 0.053 | 0.007 | 0.069 | Glutamate (mGluR8) antagonist | 0.069 0.004 DBMET01014 | DBMET01014 | |
| 0.139 | 0.094 | 0.171 | Interferon gamma antagonist | 0.171 0.056 DBMET01014 | DBMET01014 | |
| 0.074 | 0.03 | 0.082 | Trypsin inhibitor | 0.082 0.026 DBMET01014 | DBMET01014 | |
| 0.151 | 0.108 | 0.151 | Hepatoprotectant | 0.138 0.124 DBMET01014 | ||
| 0.054 | 0.012 | 0.058 | Baculoviral IAP repeat-containing protein inhibitor | 0.058 0.007 DBMET01014 0.047 0.03 DBMET00840 | DBMET01014 | |
| 0.068 | 0.031 | 0.073 | Cathepsin E inhibitor | 0.073 0.027 DBMET01014 0.059 0.042 DBMET00840 | DBMET01014 | |
| 0.046 | 0.01 | 0.053 | Bradykinin B2 receptor antagonist | 0.053 0.005 DBMET01014 | DBMET01014 | |
| 0.041 | 0.005 | 0.045 | HCV NS5A inhibitor | 0.045 0.004 DBMET01014 | DBMET01014 | |
| 0.088 | 0.052 | 0.197 | Factor XII inhibitor | 0.103 0.035 DBMET01014 0.197 0.006 DBMET00840 | DBMET00840 | |
| 0.069 | 0.034 | 0.069 | Nitric oxide donor | |||
| 0.065 | 0.031 | 0.065 | Human rhinovirus A protease inhibitor | 0.06 0.034 DBMET01014 | ||
| 0.051 | 0.02 | 0.065 | Glutamate (mGluR4) antagonist | 0.065 0.012 DBMET01014 | DBMET01014 | |
| 0.076 | 0.046 | 0.138 | Aminopeptidase I inhibitor | 0.138 0.015 DBMET01014 | DBMET01014 | |
| 0.049 | 0.02 | 0.054 | Leukotriene A4 hydrolase inhibitor | 0.054 0.018 DBMET01014 | DBMET01014 | |
| 0.068 | 0.039 | 0.068 | Protease 3C (Human rhinovirus) inhibitor | |||
| 0.079 | 0.052 | 0.214 | Somatostatin 1 agonist | 0.091 0.04 DBMET01014 0.214 0.006 DBMET00840 | DBMET00840 | |
| 0.044 | 0.018 | 0.08 | Bradykinin antagonist | 0.08 0.008 DBMET01014 | DBMET01014 | |
| 0.074 | 0.049 | 0.214 | Cathepsin G inhibitor | 0.084 0.041 DBMET01014 0.214 0.015 DBMET00840 | DBMET00840 | |
| 0.082 | 0.058 | 0.132 | Acetylcholine M3 receptor agonist | 0.132 0.029 DBMET00840 | DBMET00840 | |
| 0.036 | 0.013 | 0.044 | Bradykinin B2 receptor agonist | 0.044 0.01 DBMET01014 | DBMET01014 | |
| 0.032 | 0.009 | 0.032 | Elastase 2A inhibitor | 0.028 0.01 DBMET01014 | ||
| 0.032 | 0.009 | 0.032 | Elastase 2 inhibitor | 0.028 0.01 DBMET01014 | ||
| 0.047 | 0.025 | 0.059 | Glutamate (mGluR group III) antagonist | 0.059 0.014 DBMET01014 | DBMET01014 | |
| 0.046 | 0.027 | 0.057 | Opioid kappa receptor agonist | 0.057 0.02 DBMET01014 | DBMET01014 | |
| 0.032 | 0.012 | 0.046 | Baculoviral IAP repeat-containing protein 4 inhibitor | 0.046 0.005 DBMET01014 | DBMET01014 | |
| 0.044 | 0.028 | 0.064 | Cholecystokinin antagonist | 0.064 0.017 DBMET01014 | DBMET01014 | |
| 0.097 | 0.081 | 0.097 | Mucolytic | |||
| 0.044 | 0.032 | 0.071 | Neurotensin receptor antagonist | 0.071 0.02 DBMET01014 | DBMET01014 | |
| 0.05 | 0.04 | 0.061 | Opioid agonist | 0.061 0.029 DBMET01014 | DBMET01014 | |
| 0.044 | 0.035 | 0.065 | Endothelin-converting enzyme inhibitor | 0.065 0.022 DBMET01014 | DBMET01014 | |
| 0.033 | 0.024 | 0.048 | Calcitonin receptor agonist | 0.043 0.019 DBMET01014 0.048 0.017 DBMET00840 | DBMET00840 | |
| 0.034 | 0.027 | 0.059 | Arginase inhibitor | 0.059 0.011 DBMET01014 | DBMET01014 | |
| 0.029 | 0.023 | 0.04 | Cholecystokinin B antagonist | 0.04 0.014 DBMET01014 | DBMET01014 | |
| 0.02 | 0.015 | 0.026 | Baculoviral IAP repeat-containing protein 3 inhibitor | 0.021 0.012 DBMET01014 0.026 0.005 DBMET00840 | DBMET00840 | |
| 0.042 | 0.038 | 0.049 | Opioid mu receptor agonist | 0.049 0.03 DBMET01014 | DBMET01014 | |
| 0.057 | 0.054 | 0.06 | Caspase 9 inhibitor | 0.06 0.047 DBMET01014 | DBMET01014 | |
| 0.02 | 0.017 | 0.021 | Neuraminidase (Influenza B) inhibitor | 0.021 0.015 DBMET01014 | DBMET01014 | |
| 0.015 | 0.012 | 0.025 | CC chemokine 10 receptor antagonist | 0.016 0.008 DBMET01014 0.025 0.004 DBMET00840 | DBMET00840 | |
| 0.054 | 0.052 | 0.054 | Neuraminidase inhibitor | |||
| 0.04 | 0.039 | 0.045 | Plasmin inhibitor | 0.045 0.035 DBMET01014 | DBMET01014 | |
| 0.027 | 0.026 | 0.032 | Dipeptidyl peptidase I inhibitor | 0.032 0.019 DBMET01014 | DBMET01014 | |
| 0.069 | 0.069 | 0.789 | Acetylcholine nicotinic antagonist | 0.074 0.063 DBMET01014 0.789 0.002 DBMET00840 | DBMET00840 | |
| 0.014 | 0.014 | 0.017 | Dipeptidyl peptidase IX inhibitor | 0.017 0.01 DBMET01014 | DBMET01014 | |
| 0.012 | 0.014 | 0.028 | Integrin alpha4beta1 antagonist | 0.028 0.007 DBMET01014 | DBMET01014 | |
| 0.053 | 0.054 | 0.141 | Glucagon-like peptide 1 agonist | 0.086 0.031 DBMET01014 0.141 0.01 DBMET00840 | DBMET00840 | |
| 0.013 | 0.015 | 0.015 | Dipeptidyl peptidase VIII inhibitor | 0.015 0.011 DBMET01014 | DBMET01014 | |
| 0.191 | 0.193 | 0.196 | Apoptosis antagonist | 0.196 0.184 DBMET01014 | DBMET01014 | |
| 0.061 | 0.063 | 0.07 | Glutamate (mGluR6) antagonist | 0.07 0.041 DBMET01014 | DBMET01014 | |
| 0.053 | 0.056 | 0.084 | NMDA 2C receptor antagonist | 0.084 0.023 DBMET01014 | DBMET01014 | |
| 0.031 | 0.034 | 0.084 | NMDA receptor subunit 3A antagonist | 0.084 0.011 DBMET01014 | DBMET01014 | |
| 0.031 | 0.035 | 0.408 | Nicotinic receptor beta4 subunit antagonist | 0.039 0.024 DBMET01014 0.408 0.002 DBMET00840 | DBMET00840 | |
| 0.039 | 0.043 | 0.054 | GP IIb/IIIa receptor antagonist | 0.054 0.03 DBMET01014 | DBMET01014 | |
| 0.032 | 0.037 | 0.037 | Tryptophan 5 hydroxylase inhibitor | 0.037 0.02 DBMET01014 | DBMET01014 | |
| 0.035 | 0.04 | 0.042 | Integrin alpha1beta1 antagonist | 0.042 0.017 DBMET01014 | DBMET01014 | |
| 0.015 | 0.021 | 0.018 | Tryptophan hydroxylase 1 inhibitor | 0.018 0.009 DBMET01014 | DBMET01014 | |
| 0.031 | 0.037 | 0.036 | HCV polyprotein inhibitor | 0.036 0.018 DBMET01014 | DBMET01014 | |
| 0.024 | 0.031 | 0.033 | Caspase 2 inhibitor | 0.033 0.021 DBMET01014 | DBMET01014 | |
| 0.029 | 0.037 | 0.154 | Somatostatin 1 antagonist | 0.035 0.03 DBMET01014 0.154 0.005 DBMET00840 | DBMET00840 | |
| 0.014 | 0.022 | 0.026 | Angiotensin AT2 receptor antagonist | 0.026 0.014 DBMET01014 | DBMET01014 | |
| 0.2 | 0.208 | 0.293 | Antiobesity | 0.247 0.159 DBMET01014 0.293 0.121 DBMET00840 | DBMET00840 | |
| 0.039 | 0.048 | 0.051 | Metalloproteinase-3 inhibitor | 0.051 0.032 DBMET01014 | DBMET01014 | |
| 0.028 | 0.037 | 0.039 | Carboxypeptidase B inhibitor | 0.039 0.014 DBMET01014 0.035 0.02 DBMET00840 | DBMET01014 | |
| 0.044 | 0.054 | 0.058 | Acetylcholine M2 receptor agonist | 0.058 0.032 DBMET00840 | DBMET00840 | |
| 0.02 | 0.03 | 0.047 | Lysine carboxypeptidase inhibitor | 0.047 0.008 DBMET01014 | DBMET01014 | |
| 0.094 | 0.104 | 0.489 | Cholinergic antagonist | 0.489 0.005 DBMET00840 | DBMET00840 | |
| 0.052 | 0.065 | 0.076 | Matrix metalloproteinase inhibitor | 0.076 0.039 DBMET01014 | DBMET01014 | |
| 0.042 | 0.057 | 0.054 | Aminopeptidase microsomal inhibitor | 0.054 0.044 DBMET01014 | DBMET01014 | |
| 0.112 | 0.127 | 0.133 | Sigma receptor agonist | 0.133 0.099 DBMET01014 | DBMET01014 | |
| 0.041 | 0.057 | 0.055 | Plasminogen activator inhibitor | 0.055 0.043 DBMET01014 | DBMET01014 | |
| 0.013 | 0.029 | 0.072 | Somatostatin 3 antagonist | 0.072 0.005 DBMET00840 | DBMET00840 | |
| 0.019 | 0.035 | 0.045 | AMPA 2 receptor antagonist | 0.045 0.012 DBMET01014 | DBMET01014 | |
| 0.014 | 0.031 | 0.049 | Integrin alpha4 antagonist | 0.049 0.011 DBMET01014 | DBMET01014 | |
| 0.033 | 0.051 | 0.531 | Nicotinic receptor alpha3 subunit antagonist | 0.059 0.02 DBMET01014 0.531 0.003 DBMET00840 | DBMET00840 | |
| 0.02 | 0.037 | 0.025 | NMDA 2D receptor antagonist | 0.025 0.023 DBMET01014 | DBMET01014 | |
| 0.04 | 0.057 | 0.049 | Collagenase inhibitor | 0.049 0.034 DBMET01014 | DBMET01014 | |
| 0.01 | 0.028 | 0.023 | Aminopeptidase A inhibitor | 0.023 0.009 DBMET01014 | DBMET01014 | |
| 0.089 | 0.109 | 0.496 | Acetylcholine antagonist | 0.496 0.005 DBMET00840 | DBMET00840 | |
| 0.042 | 0.065 | 0.054 | Matrix metalloproteinase (membrane-type) inhibitor | 0.054 0.039 DBMET01014 | DBMET01014 | |
| 0.021 | 0.051 | 0.075 | Integrin antagonist | 0.075 0.021 DBMET01014 | DBMET01014 | |
| 0.009 | 0.039 | 0.019 | Integrin alpha4beta7 antagonist | 0.019 0.017 DBMET01014 | DBMET01014 | |
| 0.059 | 0.089 | 0.09 | Metalloproteinase-2 inhibitor | 0.09 0.044 DBMET01014 | DBMET01014 | |
| 0.018 | 0.049 | 0.032 | LFA antagonist | 0.032 0.013 DBMET01014 | DBMET01014 | |
| 0.071 | 0.102 | 0.169 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.169 0.022 DBMET01014 | DBMET01014 | |
| 0.047 | 0.08 | 0.132 | NMDA 2 receptor antagonist | 0.132 0.02 DBMET01014 | DBMET01014 | |
| 0.071 | 0.109 | 0.114 | Falcipain 3 inhibitor | 0.114 0.058 DBMET01014 | DBMET01014 | |
| 0.122 | 0.16 | 0.138 | Lipocortins synthesis antagonist | 0.138 0.125 DBMET01014 | DBMET01014 | |
| 0.01 | 0.049 | 0.156 | Somatostatin 2 antagonist | 0.156 0.005 DBMET00840 | DBMET00840 | |
| 0.019 | 0.06 | 0.046 | Complement C3a chemotactic receptor antagonist | 0.046 0.029 DBMET01014 | DBMET01014 | |
| 0.022 | 0.062 | 0.034 | Dipeptidyl peptidase II inhibitor | 0.034 0.02 DBMET01014 | DBMET01014 | |
| 0.02 | 0.063 | 0.061 | Kainate receptor antagonist | 0.061 0.015 DBMET01014 | DBMET01014 | |
| 0.027 | 0.071 | 0.05 | Ribonucleoside-diphosphate reductase inhibitor | 0.05 0.041 DBMET01014 | DBMET01014 | |
| 0.025 | 0.069 | 0.053 | Integrin alpha5beta1 antagonist | 0.038 0.033 DBMET01014 0.053 0.015 DBMET00840 | DBMET00840 | |
| 0.01 | 0.055 | 0.114 | Somatostatin 5 antagonist | 0.114 0.005 DBMET00840 | DBMET00840 | |
| 0.021 | 0.067 | 0.614 | Melanocortin 4 antagonist | 0.614 0.003 DBMET00840 | DBMET00840 | |
| 0.022 | 0.068 | 0.038 | Growth factor receptor-bound protein 2 antagonist | 0.038 0.018 DBMET00840 | DBMET00840 | |
| 0.026 | 0.074 | 0.049 | Ribonucleotide reductase inhibitor | 0.049 0.043 DBMET01014 | DBMET01014 | |
| 0.032 | 0.08 | 0.052 | Bombesin antagonist | 0.052 0.026 DBMET00840 | DBMET00840 | |
| 0.026 | 0.076 | 0.535 | Melanocortin antagonist | 0.535 0.003 DBMET00840 | DBMET00840 | |
| 0.028 | 0.078 | 0.041 | GHS receptor agonist | 0.041 0.033 DBMET00840 | DBMET00840 | |
| 0.008 | 0.058 | 0.039 | Growth hormone releasing factor antagonist | 0.039 0.01 DBMET00840 | DBMET00840 | |
| 0.005 | 0.056 | 0.037 | Kainate receptor 1 antagonist | 0.037 0.008 DBMET01014 | DBMET01014 | |
| 0.035 | 0.088 | 0.047 | Bombesin 2 receptor antagonist | 0.047 0.038 DBMET00840 | DBMET00840 | |
| 0.025 | 0.079 | 0.095 | NMDA receptor subunit 3B antagonist | 0.095 0.011 DBMET01014 | DBMET01014 | |
| 0.042 | 0.097 | 0.065 | Kallikrein 1 inhibitor | 0.065 0.028 DBMET00840 | DBMET00840 | |
| 0.026 | 0.084 | 0.072 | Neuropeptide agonist | 0.072 0.034 DBMET00840 | DBMET00840 | |
| 0.005 | 0.066 | 0.74 | Melanocortin 3 antagonist | 0.74 0.003 DBMET00840 | DBMET00840 | |
| 0.022 | 0.084 | 0.033 | Glutamate (mGluR3) agonist | 0.033 0.02 DBMET01014 | DBMET01014 | |
| 0.079 | 0.142 | 0.125 | Alpha-N-acetylglucosaminidase inhibitor | 0.125 0.073 DBMET01014 | DBMET01014 | |
| 0.006 | 0.074 | 0.624 | Melanocortin agonist | 0.624 0.003 DBMET00840 | DBMET00840 | |
| 0.005 | 0.074 | 0.024 | VLA-4 antagonist | 0.024 0.02 DBMET01014 0.023 0.02 DBMET00840 | DBMET01014 | |
| 0.032 | 0.104 | 0.091 | Nicotinic receptor alpha4 subunit antagonist | 0.091 0.01 DBMET00840 | DBMET00840 | |
| 0.011 | 0.083 | 0.123 | Somatostatin 4 antagonist | 0.123 0.004 DBMET00840 | DBMET00840 | |
| 0.017 | 0.093 | 0.144 | Melanocortin 1 antagonist | 0.144 0.008 DBMET00840 | DBMET00840 | |
| 0.062 | 0.14 | 0.096 | Interleukin 5 antagonist | 0.096 0.046 DBMET00840 | DBMET00840 | |
| 0.005 | 0.083 | 0.429 | Melanocortin 4 agonist | 0.429 0.004 DBMET00840 | DBMET00840 | |
| 0.082 | 0.161 | 0.231 | Histone deacetylase SIRT1 inhibitor | 0.108 0.107 DBMET01014 0.231 0.021 DBMET00840 | DBMET00840 | |
| 0.069 | 0.149 | 0.117 | Glutamate receptor antagonist | 0.117 0.077 DBMET01014 | DBMET01014 | |
| 0.028 | 0.114 | 0.081 | Farnesyltransferase inhibitor | 0.081 0.012 DBMET00840 | DBMET00840 | |
| 0.011 | 0.099 | 0.258 | Melanocortin 5 antagonist | 0.258 0.003 DBMET00840 | DBMET00840 | |
| 0.114 | 0.204 | 0.14 | Phospholipase C inhibitor | 0.14 0.127 DBMET01014 | DBMET01014 | |
| 0.002 | 0.094 | 0.732 | Melanocortin 5 agonist | 0.732 0.003 DBMET00840 | DBMET00840 | |
| 0.004 | 0.096 | 0.662 | Melanocortin 1 agonist | 0.662 0.003 DBMET00840 | DBMET00840 | |
| 0.117 | 0.211 | 0.13 | Heat shock protein 70 antagonist | 0.13 0.122 DBMET01014 | DBMET01014 | |
| 0.018 | 0.115 | 0.097 | Neurokinin 2 antagonist | 0.097 0.01 DBMET00840 | DBMET00840 | |
| 0.003 | 0.101 | 0.575 | Melanocortin 3 agonist | 0.575 0.003 DBMET00840 | DBMET00840 | |
| 0.053 | 0.151 | 0.118 | Prolactin inhibitor | 0.118 0.039 DBMET01014 0.092 0.065 DBMET00840 | DBMET01014 | |
| 0.031 | 0.134 | 0.108 | Bombesin 3 receptor antagonist | 0.108 0.01 DBMET00840 | DBMET00840 | |
| 0.035 | 0.139 | 0.063 | NMDA receptor agonist | 0.063 0.043 DBMET01014 | DBMET01014 | |
| 0.092 | 0.198 | 0.137 | Hemostatic | 0.137 0.085 DBMET00840 | DBMET00840 | |
| 0.017 | 0.123 | 0.042 | Glutamate (mGluR3) antagonist | 0.042 0.019 DBMET01014 | DBMET01014 | |
| 0.01 | 0.116 | 0.036 | Kainate receptor 2 antagonist | 0.036 0.024 DBMET01014 | DBMET01014 | |
| 0.017 | 0.124 | 0.038 | Substance P antagonist | 0.038 0.03 DBMET00840 | DBMET00840 | |
| 0.063 | 0.175 | 0.324 | Nav1.4 sodium channel blocker | 0.324 0.002 DBMET00840 | DBMET00840 | |
| 0.008 | 0.128 | 0.041 | Integrin beta5 antagonist | 0.041 0.006 DBMET00840 | DBMET00840 | |
| 0.014 | 0.137 | 0.248 | Oxytocin antagonist | 0.248 0.004 DBMET00840 | DBMET00840 | |
| 0.017 | 0.143 | 0.088 | Growth hormone release inhibitor | 0.088 0.008 DBMET00840 | DBMET00840 | |
| 0.009 | 0.137 | 0.033 | Urotensin II agonist | 0.033 0.013 DBMET00840 | DBMET00840 | |
| 0.016 | 0.147 | 0.583 | Erythropoietin receptor agonist | 0.583 0.002 DBMET00840 | DBMET00840 | |
| 0.019 | 0.15 | 0.09 | Kallikrein inhibitor | 0.09 0.012 DBMET00840 | DBMET00840 | |
| 0.127 | 0.259 | 0.298 | DNA synthesis inhibitor | 0.298 0.044 DBMET00840 | DBMET00840 | |
| 0.026 | 0.161 | 0.809 | Neuronal nicotinic receptor antagonist | 0.809 0.002 DBMET00840 | DBMET00840 | |
| 0.008 | 0.144 | 0.052 | Plasma kallikrein inhibitor | 0.052 0.011 DBMET00840 | DBMET00840 | |
| 0.014 | 0.157 | 0.04 | Neurokinin 1 antagonist | 0.04 0.029 DBMET00840 | DBMET00840 | |
| 0.023 | 0.167 | 0.042 | Kainate receptor agonist | 0.042 0.026 DBMET01014 | DBMET01014 | |
| 0.014 | 0.162 | 0.028 | Motilin receptor antagonist | 0.028 0.019 DBMET00840 | DBMET00840 | |
| 0.057 | 0.211 | 0.101 | Microtubule formation inhibitor | 0.101 0.089 DBMET00840 | DBMET00840 | |
| 0.004 | 0.157 | 0.184 | Melatonin 3 antagonist | 0.184 0.004 DBMET00840 | DBMET00840 | |
| 0.011 | 0.167 | 0.255 | Somatostatin agonist | 0.255 0.005 DBMET00840 | DBMET00840 | |
| 0.041 | 0.197 | 0.313 | Antihistaminic | 0.313 0.009 DBMET00840 | DBMET00840 | |
| 0.104 | 0.286 | 0.173 | Superoxide dismutase inhibitor | 0.173 0.151 DBMET01014 | DBMET01014 | |
| 0.015 | 0.197 | 0.059 | Neurokinin antagonist | 0.059 0.025 DBMET00840 | DBMET00840 | |
| 0.013 | 0.2 | 0.093 | Somatostatin 5 agonist | 0.093 0.005 DBMET00840 | DBMET00840 | |
| 0.008 | 0.197 | 0.05 | 1,3-Beta-glucan synthase inhibitor | 0.05 0.003 DBMET00840 | DBMET00840 | |
| 0.028 | 0.221 | 0.301 | Histamine antagonist | 0.301 0.01 DBMET00840 | DBMET00840 | |
| 0.03 | 0.224 | 0.133 | Antiadrenergic | 0.133 0.041 DBMET00840 | DBMET00840 | |
| 0.028 | 0.228 | 0.13 | Adrenaline antagonist | 0.13 0.04 DBMET00840 | DBMET00840 | |
| 0.03 | 0.23 | 0.087 | Acetylcholine agonist | 0.087 0.058 DBMET00840 | DBMET00840 | |
| 0.006 | 0.209 | 0.115 | Complement C5a chemotactic receptor antagonist | 0.115 0.005 DBMET00840 | DBMET00840 | |
| 0.007 | 0.216 | 0.031 | Geranylgeranyltransferase I inhibitor | 0.031 0.008 DBMET00840 | DBMET00840 | |
| 0.018 | 0.235 | 0.084 | Glutamate receptor agonist | 0.084 0.049 DBMET01014 | DBMET01014 | |
| 0.005 | 0.228 | 0.03 | Bombesin 3 receptor agonist | 0.03 0.006 DBMET00840 | DBMET00840 | |
| 0.023 | 0.248 | 0.102 | Bombesin 1 receptor agonist | 0.102 0.017 DBMET00840 | DBMET00840 | |
| 0.014 | 0.241 | 0.037 | AMPA 4 receptor antagonist | 0.037 0.032 DBMET01014 | DBMET01014 | |
| 0.006 | 0.232 | 0.048 | Bombesin agonist | 0.048 0.005 DBMET00840 | DBMET00840 | |
| 0.004 | 0.238 | 0.014 | Somatostatin 2 agonist | 0.014 0.011 DBMET00840 | DBMET00840 | |
| 0.01 | 0.246 | 0.039 | Cyclophilin A inhibitor | 0.039 0.012 DBMET00840 | DBMET00840 | |
| 0.047 | 0.283 | 0.113 | Nav1.1 sodium channel blocker | 0.113 0.053 DBMET00840 | DBMET00840 | |
| 0.015 | 0.26 | 0.05 | Somatostatin 4 agonist | 0.05 0.015 DBMET00840 | DBMET00840 | |
| 0.032 | 0.281 | 0.077 | Gonadotropin-releasing hormone receptor agonist | 0.077 0.02 DBMET00840 | DBMET00840 | |
| 0.004 | 0.255 | 0.323 | Histamine H3 receptor antagonist | 0.323 0.004 DBMET00840 | DBMET00840 | |
| 0.018 | 0.27 | 0.308 | CXC chemokine 4 receptor antagonist | 0.308 0.005 DBMET00840 | DBMET00840 | |
| 0.008 | 0.267 | 0.059 | Histone deacetylase class IV inhibitor | 0.059 0.011 DBMET00840 | DBMET00840 | |
| 0.008 | 0.267 | 0.059 | Histone deacetylase 11 inhibitor | 0.059 0.011 DBMET00840 | DBMET00840 | |
| 0.003 | 0.266 | 0.018 | CXC chemokine 4 receptor agonist | 0.018 0.007 DBMET00840 | DBMET00840 | |
| 0.011 | 0.307 | 0.565 | Nicotinic receptor alpha7 subunit antagonist | 0.565 0.002 DBMET00840 | DBMET00840 | |
| 0.008 | 0.309 | 0.022 | Vasopressin 1 agonist | 0.022 0.014 DBMET00840 | DBMET00840 | |
| 0.014 | 0.318 | 0.035 | Vasopressin 1A agonist | 0.035 0.009 DBMET00840 | DBMET00840 | |
| 0.034 | 0.339 | 0.119 | Triose-phosphate isomerase inhibitor | 0.119 0.033 DBMET00840 | DBMET00840 | |
| 0.008 | 0.316 | 0.024 | Somatostatin 3 agonist | 0.024 0.006 DBMET00840 | DBMET00840 | |
| 0.058 | 0.374 | 0.383 | Tumour necrosis factor alpha release inhibitor | 0.383 0.03 DBMET00840 | DBMET00840 | |
| 0.008 | 0.328 | 0.041 | Oxytocin agonist | 0.041 0.031 DBMET00840 | DBMET00840 | |
| 0.056 | 0.379 | 0.122 | NOS3 expression enhancer | 0.122 0.111 DBMET00840 | DBMET00840 | |
| 0.005 | 0.335 | 0.058 | Histone deacetylase 4 inhibitor | 0.058 0.01 DBMET00840 | DBMET00840 | |
| 0.027 | 0.364 | 0.13 | Histone deacetylase class III inhibitor | 0.13 0.061 DBMET00840 | DBMET00840 | |
| 0.008 | 0.351 | 0.029 | Antidiuretic hormone agonist | 0.029 0.016 DBMET00840 | DBMET00840 | |
| 0.007 | 0.355 | 0.17 | Vasopressin 2 antagonist | 0.17 0.004 DBMET00840 | DBMET00840 | |
| 0.005 | 0.355 | 0.278 | Antidiuretic hormone antagonist | 0.278 0.004 DBMET00840 | DBMET00840 | |
| 0.041 | 0.392 | 0.4 | Interleukin antagonist | 0.4 0.031 DBMET00840 | DBMET00840 | |
| 0.001 | 0.361 | 0.036 | Melatonin 5 antagonist | 0.036 0.003 DBMET00840 | DBMET00840 | |
| 0.004 | 0.386 | 0.037 | Vasopressin 1B antagonist | 0.037 0.011 DBMET00840 | DBMET00840 | |
| 0.023 | 0.408 | 0.221 | GABA C receptor agonist | 0.221 0.017 DBMET00840 | DBMET00840 | |
| 0.062 | 0.466 | 0.21 | Neuropeptide Y2 antagonist | 0.21 0.103 DBMET00840 | DBMET00840 | |
| 0.004 | 0.424 | 0.041 | CXC chemokine receptor agonist | 0.041 0.013 DBMET00840 | DBMET00840 | |
| 0.004 | 0.434 | 0.234 | Vasopressin 1 antagonist | 0.234 0.004 DBMET00840 | DBMET00840 | |
| 0.024 | 0.455 | 0.12 | Breast cancer-resistant protein inhibitor | 0.12 0.04 DBMET00840 | DBMET00840 | |
| 0.064 | 0.499 | 0.222 | Antibacterial | 0.222 0.205 DBMET00840 | DBMET00840 | |
| 0.005 | 0.447 | 0.022 | Geranylgeranyltransferase inhibitor | 0.022 0.016 DBMET00840 | DBMET00840 | |
| 0.026 | 0.47 | 0.296 | Nav1.3 sodium channel blocker | 0.296 0.009 DBMET00840 | DBMET00840 | |
| 0.019 | 0.473 | 0.088 | Histamine H2 receptor antagonist | 0.088 0.049 DBMET00840 | DBMET00840 | |
| 0.004 | 0.46 | 0.055 | Histone deacetylase 10 inhibitor | 0.055 0.01 DBMET00840 | DBMET00840 | |
| 0.004 | 0.462 | 0.171 | Vasopressin 1A antagonist | 0.171 0.004 DBMET00840 | DBMET00840 | |
| 0.03 | 0.496 | 0.118 | Nav1.2 sodium channel blocker | 0.118 0.086 DBMET00840 | DBMET00840 | |
| 0.006 | 0.478 | 0.071 | Chemokine receptor agonist | 0.071 0.017 DBMET00840 | DBMET00840 | |
| 0.002 | 0.496 | 0.034 | Nicotinic alpha3beta4 receptor agonist | 0.034 0.015 DBMET00840 | DBMET00840 | |
| 0.023 | 0.558 | 0.257 | Cell wall synthesis inhibitor | 0.257 0.015 DBMET00840 | DBMET00840 | |
| 0.072 | 0.615 | 0.167 | MAP kinase kinase 5 inhibitor | 0.167 0.093 DBMET00840 | DBMET00840 | |
| 0.021 | 0.569 | 0.077 | Kallikrein 7 inhibitor | 0.077 0.017 DBMET00840 | DBMET00840 | |
| 0.006 | 0.556 | 0.075 | CXC chemokine receptor antagonist | 0.075 0.043 DBMET00840 | DBMET00840 | |
| 0.004 | 0.564 | 0.058 | Histone deacetylase 7 inhibitor | 0.058 0.016 DBMET00840 | DBMET00840 | |
| 0.021 | 0.594 | 0.144 | Alpha 2d adrenoreceptor antagonist | 0.144 0.011 DBMET00840 | DBMET00840 | |
| 0.01 | 0.602 | 0.096 | Histone deacetylase SIRT3 inhibitor | 0.096 0.011 DBMET00840 | DBMET00840 | |
| 0.005 | 0.598 | 0.055 | Histone deacetylase 9 inhibitor | 0.055 0.013 DBMET00840 | DBMET00840 | |
| 0.003 | 0.599 | 0.072 | Alpha 1a adrenoreceptor antagonist | 0.072 0.049 DBMET00840 | DBMET00840 | |
| 0.008 | 0.605 | 0.164 | Alpha adrenoreceptor antagonist | 0.164 0.034 DBMET00840 | DBMET00840 | |
| 0.004 | 0.603 | 0.452 | Histamine H3 receptor agonist | 0.452 0.002 DBMET00840 | DBMET00840 | |
| 0.004 | 0.635 | 0.114 | Alpha 1 adrenoreceptor antagonist | 0.114 0.039 DBMET00840 | DBMET00840 | |
| 0.077 | 0.719 | 0.175 | 5 Hydroxytryptamine 3E antagonist | 0.175 0.119 DBMET00840 | DBMET00840 | |
| 0.004 | 0.652 | 0.039 | Histone deacetylase class IIa inhibitor | 0.039 0.017 DBMET00840 | DBMET00840 | |
| 0.005 | 0.66 | 0.085 | Histone deacetylase SIRT2 inhibitor | 0.085 0.041 DBMET00840 | DBMET00840 | |
| 0.024 | 0.681 | 0.107 | Interleukin 2 antagonist | 0.107 0.072 DBMET00840 | DBMET00840 | |
| 0.017 | 0.675 | 0.085 | MAP kinase kinase 7 inhibitor | 0.085 0.033 DBMET00840 | DBMET00840 | |
| 0.013 | 0.672 | 0.114 | Alpha 2b adrenoreceptor antagonist | 0.114 0.063 DBMET00840 | DBMET00840 | |
| 0.008 | 0.669 | 0.171 | Alpha 2 adrenoreceptor antagonist | 0.171 0.022 DBMET00840 | DBMET00840 | |
| 0.004 | 0.667 | 0.03 | Histone deacetylase 5 inhibitor | 0.03 0.025 DBMET00840 | DBMET00840 | |
| 0.011 | 0.677 | 0.209 | Nav1.6 sodium channel blocker | 0.209 0.016 DBMET00840 | DBMET00840 | |
| 0.008 | 0.684 | 0.163 | Alpha 2a adrenoreceptor antagonist | 0.163 0.02 DBMET00840 | DBMET00840 | |
| 0.008 | 0.686 | 0.174 | Polo-like kinase-1 inhibitor | 0.174 0.01 DBMET00840 | DBMET00840 | |
| 0.009 | 0.689 | 0.095 | Histamine N-methyltransferase inhibitor | 0.095 0.051 DBMET00840 | DBMET00840 | |
| 0.004 | 0.697 | 0.045 | Histamine H2 receptor agonist | 0.045 0.027 DBMET00840 | DBMET00840 | |
| 0.015 | 0.718 | 0.08 | mTOR complex 2 inhibitor | 0.08 0.069 DBMET00840 | DBMET00840 | |
| 0.017 | 0.725 | 0.059 | Alpha 1b adrenoreceptor agonist | 0.059 0.021 DBMET00840 | DBMET00840 | |
| 0.003 | 0.726 | 0.031 | Histone deacetylase 3 inhibitor | 0.031 0.014 DBMET00840 | DBMET00840 | |
| 0.003 | 0.739 | 0.177 | Alpha adrenoreceptor agonist | 0.177 0.011 DBMET00840 | DBMET00840 | |
| 0.018 | 0.768 | 0.089 | mTOR complex 1 inhibitor | 0.089 0.088 DBMET00840 | DBMET00840 | |
| 0.003 | 0.757 | 0.096 | Alpha 1 adrenoreceptor agonist | 0.096 0.018 DBMET00840 | DBMET00840 | |
| 0.007 | 0.78 | 0.105 | 5 Hydroxytryptamine 3A agonist | 0.105 0.07 DBMET00840 | DBMET00840 | |
| 0.003 | 0.779 | 0.262 | Histamine agonist | 0.262 0.003 DBMET00840 | DBMET00840 | |
| 0.004 | 0.78 | 0.037 | Histone deacetylase 2 inhibitor | 0.037 0.02 DBMET00840 | DBMET00840 | |
| 0.004 | 0.783 | 0.03 | Histone deacetylase 6 inhibitor | 0.03 0.015 DBMET00840 | DBMET00840 | |
| 0.004 | 0.783 | 0.03 | Histone deacetylase class IIb inhibitor | 0.03 0.015 DBMET00840 | DBMET00840 | |
| 0.003 | 0.784 | 0.086 | 5 Hydroxytryptamine 3 antagonist | 0.086 0.022 DBMET00840 | DBMET00840 | |
| 0.002 | 0.789 | 0.086 | 5 Hydroxytryptamine 3A antagonist | 0.086 0.026 DBMET00840 | DBMET00840 | |
| 0.003 | 0.796 | 0.085 | Alpha 2 adrenoreceptor agonist | 0.085 0.021 DBMET00840 | DBMET00840 | |
| 0.003 | 0.821 | 0.033 | Alpha 2d adrenoreceptor agonist | 0.033 0.008 DBMET00840 | DBMET00840 | |
| 0.004 | 0.824 | 0.029 | Histone deacetylase class II inhibitor | 0.029 0.019 DBMET00840 | DBMET00840 | |
| 0.003 | 0.825 | 0.09 | Histamine H4 receptor antagonist | 0.09 0.006 DBMET00840 | DBMET00840 | |
| 0.007 | 0.849 | 0.124 | Phosphodiesterase XI inhibitor | 0.124 0.018 DBMET00840 | DBMET00840 | |
| 0.007 | 0.849 | 0.124 | Phosphodiesterase 11A inhibitor | 0.124 0.018 DBMET00840 | DBMET00840 | |
| 0.002 | 0.861 | 0.043 | Histone deacetylase class I inhibitor | 0.043 0.024 DBMET00840 | DBMET00840 | |
| 0.004 | 0.868 | 0.207 | EphA2 antagonist | 0.207 0.012 DBMET00840 | DBMET00840 | |
| 0.003 | 0.871 | 0.095 | Histone deacetylase inhibitor | 0.095 0.02 DBMET00840 | DBMET00840 | |
| 0.007 | 0.883 | 0.117 | Corticotropin releasing factor 2 receptor antagonist | 0.117 0.004 DBMET00840 | DBMET00840 | |
| 0.004 | 0.886 | 0.112 | Polo-like kinase-4 inhibitor | 0.112 0.064 DBMET00840 | DBMET00840 | |
| 0.003 | 0.901 | 0.157 | Sodium channel blocker | 0.157 0.053 DBMET00840 | DBMET00840 | |
| 0.003 | 0.901 | 0.217 | Sodium channel (voltage-gated) blocker | 0.217 0.024 DBMET00840 | DBMET00840 | |
| 0.004 | 0.913 | 0.282 | Nav1.5 sodium channel blocker | 0.282 0.006 DBMET00840 | DBMET00840 | |
| 0.004 | 0.93 | 0.095 | Ephrin antagonist | 0.095 0.068 DBMET00840 | DBMET00840 | |
| 0.001 | 0.927 | 0.119 | Nav1.7 sodium channel blocker | 0.119 0.017 DBMET00840 | DBMET00840 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |